Webinar: What is needed to progress ATMPs in Europe? Road to Phacilitate's Advanced Therapies Europe by Phacilitate

What is needed to progress ATMPs in Europe? Road to Phacilitate's Advanced Therapies Europe

About

Ahead of Phacilitate’s Advanced Therapies Europe, Join key industry experts to discuss the current state and trajectory of ATMPs in the EU.

As the world has seen seismic shifts in the funding, technical and commercial landscape for cell and gene therapies, it is important to identify Europe’s evolving role in the global ecosystem, how we can establish and shore-up European bioregions that can translate, develop and manufacture the next generation of ATMPs.

This is a must-attend, plenary-level meeting for translational, technical and commercial cell and gene therapy experts.

Agenda

Short intro from Ry Leahy & Becky Johnson (Phacilitate)

Panel:
Where is Europe in the global standing of cell and gene therapies?
Where are the gaps/what are the core infrastructure needs?
- Technical, analytical and scale needs
- Facility and logistical needs

How do we ensure access for patients with European ATMPs?
- Access through cost reduction
- Ensuring robust supply

What role does Europe play in advancing global ATMPs?

Presenters

Lindsay Davies

NextCell Pharma AB, QVance, ISCT & Karolinska Institutet

Lindsay Davies is the Chief Scientific Officer of NextCell Pharma in Stockholm, Sweden and CEO of QVance. Lindsay is a SME in mesenchymal stromal cell biology and cell therapy, having worked in the field for the last 20 years. She completed her PhD in orthopaedic biochemistry at Cardiff University in the UK, focussing on cell therapy for cartilage repair; springboarding her into a career in stem/stromal cell biology within the UK. She subsequently moved to Karolinska Institutet, Sweden and as an Associate Professor Dr Davies worked with basic science and clinical trial development using stromal cells from different tissue sources.

In 2020, Dr Davies joined NextCell Pharma, a cell therapy company, developing stromal cell products for usage in multiple clinical indications. She has supported the company´s movement from a phase I company, with one initial clinical trial to four active Phase I/II trials, international expansion, and a phase III clinical trial and commercialisation programme in development.
Dr Davies continues to work closely with academia in the space of cell therapy development. In addition to her academic and industrial roles, Lindsay has recently been appointed as VP Elect for Europe for the International Society for Cell and Gene Therapy and inaugural Chair for the European Industry Committee for ISCT, as well as several committees related to process development and commercialisation

Miguel Forte

Kiji Therapeutics & ISCT

President and Board of Directors chair of the International Society of Cell and Gene Therapy (ISCT) from June 2024. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the Committee to better represent the industrial translational objectives and needs of society membership.

CEO and Co-Founder of Kiji Therapeutics, member of the Board of StemBond and Swarm, consulting through mC4Tx to several organizations, Professor at the Lisbon University and Board of Directors and Executive Committee member for Alliance for Regenerative Medicine (ARM).

Previously CEO of Bone Therapeutics (2019-2022) leading the listed company through strategic refocus, several raises and a successful M&A transaction. Before that, CEO of Zelluna Immunotherapy (2017-2019), where he established the corporate structure, raised successfully, built the team and launched the strategy for solid tumors allogeneic C>. From 2010-2017 was CMO/COO of TxCell, establishing and leading the professional C> product translation development for autoimmune diseases. Participated on the company IPO and several successful raises. From 2006-2010 was VP of Global Medical Affairs at UCB contributing to the development of the biologics portfolio, product approval and launch. In 2004, joined Nabi Pharmaceuticals as the VP of Medical/Regulatory Affairs for Europe, leading from inception the creation of the vaccine company in Europe.

After several public sector clinical, academic, and regulatory positions in Portugal and at the European Medicines Agency (EMA), namely as CHMP member, spent six years with BMS (1998-2003) as Country Medical Director, Executive Director, and VP of International Medical in Portugal and Belgium.

Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a Ph.D. in Immunology, University of Birmingham, and a certificate on Health Technologies Economics, Stockholm School of Economics. He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.

Montse Daban Marin

BioRegion of Catalonia (BioCat) & Coalition for European BioRegions (CEBR)

Montserrat holds master's degrees in science communication with a focus on medicine, biology, and diplomacy and foreign relations. She also holds a doctorate in molecular biology.

She has over 35 years of experience as a life sciences and scientific communication researcher, having worked in Cleveland, Barcelona, Lille, France, and Ohio (OH, EE.UU). In addition to her work as a scientific publisher at Editorial Rubes, she has advised the Department of Research and Universities of the Generalitat of Catalonia on R&D+i policies and international relations.

Montserrat has worked at Biocat since 2006 in a variety of roles pertaining to international relations, scientific policy, and communication. She currently serves as the Council of European Bioregions (CEBR) president.

Montserrat speaks five languages, including Catalan, Spanish, English, French and Italian. Their interests reach a wide range of areas, such as communication, strategy, ecosystems, innovation, internationalization, gender, open science, impact assessment, double transformation, digitization and collaboration.

Bo Wiinberg

Novo Nordisk Foundation Cellerator

Bo is a seasoned leader with extensive experience from both academia, the pharmaceutical and biotech sectors, focusing on strategic and operational leadership throughout the drug development value chain.

Bo was previously an Entrepreneur in Residence at the Bio Innovation Institute and at Novo Nordisk A/S, Bo held several senior positions over the years, including Head of Strategy & Operations for the Stem Cell unit. Bo is a Doctor of Veterinary Medicine, earned a PhD from the University of Copenhagen and has numerous publications in peer-reviewed journals. Additionally, he has executive education programs in corporate governance and business leadership.

Becky Johnson-Kent

Phacilitate

Ryan Leahy

Phacilitate

Ry is a science communication leader and VP of Research/Director of Strategic Partnerships at Phacilitate, is a patient advocate for his own rare disease (Eosinophilic Esophagitis), and a strategic engagement and science communications consultant under Science Communication Foundry. Ry remains a Visiting academic at Linacre College, Oxford since 2017.

First Name*

Last Name*

Email Address*

Job Title*

Company Name*

Where are you based?*

What's Your Organizations Main Activity*

Are you a resident of EU/UK or EEA?*